Moderna to become marketing authorization holder in Japan for Spikevax

Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period

USFDA accepts dupilumab for priority review in adults with prurigo nodularis

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved

NATCO launches first generic version of Nexavar Tablets in the US

The product will be launched by NATCO's commercial partner Viatris.

Novavax initiates phase 3 trial of its COVID-19 omicron booster

Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19

ENTOD Pharmaceuticals gets DCGI nod to carry out the phase 3 trials of 0.05% atropine eye drops

Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children

Mezzion Pharma receives clear FDA path forward for the approval of Udenafil for single ventricle heart disease

Jubilant HollisterStier enters into agreement of $149.6 mn with US Govt to expand critical vaccine manufacturing capacity

This agreement is in addition to the $92 million filling line expansion announced in November 2021

Strides receives USFDA approval for Ibuprofen Oral Suspension

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)

Medisca inks distribution license with SUANFARMA

Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price

USFDA approves Novartis Kymriah CAR-T cell therapy

68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile